AMCP Nexus 2022

An overview of recently passed legislation and proposals anticipated in the coming year Read More ›

A comprehensive review of the role of prescriber feedback reports in managing drug utilization Read More ›

Session exploring the roles of community engagement, clinical trials, and formulary management in addressing health disparities Read More ›

In patients with relapsed or refractory LBCL treated with lisocabtagene maraleucel, post-infusion monitoring costs were lower in the outpatient setting versus the inpatient setting Read More ›

Survey finds that the majority of patients were in favor of or indifferent to treatment in the inpatient setting if better outcomes could be achieved Read More ›

Survey of healthcare decision makers found that preapproval information exchange could have a positive impact on shortening formulary decision-making timelines Read More ›

Multi-cancer early detection screening can achieve better cancer detection and comparable or improved cost-effectiveness Read More ›

Study utilizing an epidemiological model estimates the incidence of DLBCL and evaluates treatment patterns by line of therapy Read More ›

An analysis found that commercial health insurers do not issue coverage policies more quickly for specialty drugs approved through FDA-expedited review programs Read More ›

Claims-based analysis assesses healthcare resource utilization and standard-of-care costs among US patients with relapsed or refractory MCL Read More ›

Page 1 of 2

Conference Correspondent Coverage is Brought to You by the Publishers of:
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications